Sales dropped 6.2% to $536.9 million compared with $572.6 million for the second quarter of 2019. In particular, revenues in the company's clinical diagnostics segment decreased by 20.7%.

However, net income for Q2 was $966.4 million versus $598.8 million in the second quarter of 2019 primarily due to the recognition of changes in the fair market value of equity securities related to the holdings of Bio-Rad Laboratories' investment in Sartorius.

Year-to-date net income reached $1.65 billion compared with $1.46 billion for the same period last year. Given the situation with the pandemic, the firm thinks its third quarter 2020 year-over-year currency-neutral sales may be flat to up 5%.

BioRad teams with Biodesix on COVID-19 total antibody test
Bio-Rad Laboratories and lung cancer diagnostics firm Biodesix have joined forces to launch a serology test for detecting COVID-19 antibodies.

Bio-Rad COVID-19 test cleared in U.S.
Bio-Rad Laboratories has garnered emergency use authorization from the U.S. Food and Drug Administration for its droplet digital polymerase chain reaction...